Subcutaneous IL-6 Inhibitor Sarilumab vs. Standard Care in Hospitalized Patients With Moderate-To-Severe COVID-19: An Open Label Randomized Clinical Trial
García-Vicuña et al., Frontiers in Medicine, doi:10.3389/fmed.2022.819621
https://c19early.org/garciavicuna.html